BRAF and melanoma: Proteomic analysis of CRISPR/Cas derived PTRF knockouts demonstrated that two markers (PTRF and IGFBP7), which are considerably overexpressed, have an effective contribution to MAPKi resistance and EMT as well as promoting cell adhesion and sphere formation in melanoma cells harboring BRAF mutations.